Medicenna Therapeutics (TSX:MDNA) Net Issuance of Preferred Stock : C$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Medicenna Therapeutics's net issuance of preferred for the three months ended in Dec. 2023 was C$0.00 Mil. The number is 0, which means that Medicenna Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Medicenna Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil.

Medicenna Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Medicenna Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Net Issuance of Preferred Stock Chart

Medicenna Therapeutics Annual Data

Trend

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Medicenna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Medicenna Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Medicenna Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Executives

Albert George Beraldo	Director
Chandra Panchal	Director

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines